APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaf ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader ...
The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated ...
The firm also announced the submission of the Biologic License Application (BLA) for their Avance Nerve Graft, which the FDA has accepted for priority review, expected to conclude by September 2025.
The firm also announced the submission of the Biologic License Application (BLA) for their Avance Nerve Graft, which the FDA has accepted for priority review, expected to conclude by September 2025.
The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated ...
Canaccord Genuity adjusted their valuation of AxoGen, Inc. (NASDAQ: NASDAQ:AXGN), increasing the price target to $22.00 from the previous $18.00. The firm reaffirmed its Buy rating on the company's ...
The company’s strategic advancements include FDA acceptance of its Biologics License Application for Avance Nerve Graft and promising engagement at industry events. Axogen aims to hit the high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback